THC-rich and CBD-rich Cannabis products

Determination of the right Cannabis strain, dosage form, delivery system and dosing for a specific patient and medical condition is a challenging process. The active ingredients of the Cannabis plant (cannabinoids) have distinct pharmacological uses, such as pain relief, anti-nausea, antioxidants, neurological regulation, and anti-inflammatory, but there are only a bonafide few clinical trials to date.

The main cannabinoids in the Cannabis plant are THC and CBD and Cannabis products are classified in most cases based on THC and CBD concentrations. There are many other cannabinoids which have been studied less such as CBG, CBC, CBL, and CBN.

The higher the concentration of cannabinoids in the dose, the more potent the product is. According to the concentrations of these active ingredients, cannabis products can be generally divided into two groups of THC-rich cannabis products and CBD-rich cannabis products.

What is THC?

THC is Tetrahydrocannabinol is the main Phyto-Cannabinoid in the Cannabis plant which offers all the psychoactive effect. THC has a variety of physiological effects and is commonly used as an effective treatment for anti-shaking, anti-nausea, appetite-boosting, and anti-inflammatory. It also has other effects such as relaxation, visual and auditory changes, and a change in smell.

What is CBD?

CBD is Cannabidiol, a Phyto-Cannabinoid which is not associated with any psychoactive effect. Its associated field of activity includes anti-inflammatory, anti-tremor, anti-oxidant, anti-psychoactive activity, thus reducing the psychoactive effects of THC, neuroprotective activity and anti-anxiety activity.

The therapeutic potential of CBD and THC

Recent studies provide a reasonable basis that supports cannabis’ therapeutic potential for a number of physiological and psychological conditions, the most important of which are anti-inflammatory conditions, anti-spasmodic conditions, a variety of anxiety disorders including PTSD and extended sleep time.

As reported in many studies, CBD incorporation in the cannabis product neutralizes and reduces undesired side effects from THC. In addition, studies support the fact that even with acute administration of CBD, there are no significant toxic effects in humans, regardless of whether the administration is oral or intravenous.

THC and CBD correct dosing

Patient’s sensitivity to THC is a key factor in deciding how to adjust the dose accordingly in relation to the THC/CBD ratio.

Treatment with CBD-rich cannabis products carries a lower risk of adverse side effects.

It appears that the only significant risk that is likely from CBD is its potential to cause immune-suppression, Cannabinoids Inhibit Nucleoside Transporter to Mediate Immuno-suppression, in high CBD doses. Low CBD dosing was found to stimulate the immune system. Therefore, in most cases, physicians may avoid recommending a high CBD dose for patients with depressed immune systems until further research is carried out.

A treatment program based on CBD-rich cannabis products is desirable in many cases, especially when it comes to one or more of the following reasons:

  • Where there is a reported or suspected sensitivity to THC, whether before or after cannabis initiation.
  • For the treatment of confirmed indications including inflammatory conditions, spasmodic conditions, PTSD and sleep problems.
  • For chronically ill children under the age of 18 – for whom the nervous system is still in development and there is no clear scientific information on how THC affects this development.
  • For patients with liver cancer (Hepatoma) who should not use THC.

About Cannabis GxP consultancy

Cannabis GXP is proud to stand at the forefront of the Cannabis industry in Israel and worldwide thanks to many years of experience in these areas.

Our team is compelled to spread the message of the importance of cannabis science, regulation and standardization as the world enters a new era of cannabis legislation.

We aim to position our clients with their best foot forward when it comes to anything and everything cannabis related.

Our vast expertise allows us to assist companies in a wide range of services and needs: Anything from Cannabis R&D, growing and manufacturing, new products development, facility design, technology, Quality Assurance, Good Practices (GAP/GMP/GLP/GDP/GCP), staff training, local and global regulations.

Cannabis GxP is a subsidiary company of Bio-Chem Ltd. (2007), a consultancy firm for the Pharmaceutical field, medical devices, Cosmetics and food supplements industry based in Israel.

Our cannabis consultancy services include:

  • Product development, delivery system & clinical trials
  • Growing, Manufacturing and Lab Facilities Design
  • Quality Assurance and Good Practices (GxP)
  • Cultivation & Product Manufacturing Technology
  • New product Regulations and Submissions
  • Qualification & Validation
  • Risk Assessment
  • Staff training

If you need one or several of our services, we will be more than happy to assist.

Please do not hesitate to contact us for further information.